Source: https://www.klausmann.de/aerzte/
Timestamp: 2019-04-21 10:54:04+00:00

Document:
in unserer Facharztpraxis kümmert sich ein großartiges Team um Ihr gesundheitliches Wohl.
Sie als Patient stehen im Mittelpunkt all’ unserer Anstren­gungen. Wir bieten Ihnen ein ganz­heitliches Behandlungs­konzept auf der Basis des aktuellen medizinischen Fortschritts.
Stimulation des oxidativen Stoffwechsels von Granulozyten durch rH.GM-CSF und konditioniertes Medium der Blasenkarzinomzellinie 5637.
Modulation of functions of granulocytes by human GM-CSF and possible complications of GM-CSF therapy.
Influence of recombinant human granulocyte-macrophage colony stimulating factor on granulocyte functions.
Granulocyte-macrophage colony-stimulating factor binding sites and oxidative metabolism in human granulocytes.
Blood erythroid progenitors (CFU.E and BFU.E) in acute lymphoblastic leukemia.
Collagen gel cultures for detection of spared hematopoietic progenitors in Asta Z 7557 purged bone marrow.
Effects of recombinant human interleukin-3 in aplastic anemia.
A. Ganser, A. Lindemann, G. Seipelt, O. Ottmann, M. Eder, S. Falk, F. Hermann, J.P. Kaltwasser, P. Meusers, M. Klausmann, J. Frisch, G. Schulz, R. Mertelsmann, d. Hoelzer.
Effects of recombinant human Interleukin-3 in patients with myelodysplastic syndromes.
Effect of rH.GM-CSF on hematopoietic reconstitution after chemotherapy in small cell lung cancer.
GM-CSF versus G-CSF in the treatment of infectious complication in Felty´s syndrome-a case report.
Felty´s syndrome: favorable response to GM-CSF in the acute phase.
Granulocyte-Monocyte Colony-stimulating factor levels during hemodialysis-induced leukopenia.
Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b.
Effect of treatment with amifostin used as a single agent in patients with refractory anemia on clinical outcome and serum TNF alpha levels.
Colony-stimulating factors in solid tumors: paraneoplastic production and growth -modulating activity.
Effect of rH. GM-CSF on hematopoietic reconstitution after chemotherapy in small cell lung cancer.
Abstract second international conference on small cell lung cancer, Ravenna Italy , May11-12,1990.
Influence of the schedule of GM-CSF application on chemotherapy-induced myelosuppression.
Développement des progéniteurs granulomonocytaires humains en gel de collagène: analyse des résultats et comparaison avec l´agar.
Révélation des CFU-GM résiduelles après chimiothérapie in vitro: interet du gel de collagène et comparaison avec l´agar.
Autocrine growth factors in conditioned media of permanent cultures of acute myelomonocytic leukemia.
Action of recombinant human GM-CSF on granulocyte functions.
Effect of rH.GM-CSF on hematopoietic reconstitution after high dose chemotherapy in patients with small cell lung cancer.
rH.GM-CSF allows treatment intensification in patients with small cell lung cancer.
Phase I/II trial of recombinant human interleukin-3 in patients with aplastic anemia.
A. Ganser, A. Lindemann, O.G. Ottmann, G. Seipelt, M. Eder, P. Meusers, M. Klausmann, F. Hermann, G. Schulz, R. Mertelsmann, D. Hoelzer.
Effects of different hematopoietic growth factors (IL-3, GM-CSF, G-CSF) on the in vitro growth of human leukemia and tumor cells.
High-dose Ara-C, Cyclophosphamide and VP16 with autologous bone marrow transplantation for acute myeloid leukemia in first remission.
GM-CSF versus G-CSF in the treatment of infectious complications in Felty´s Syndrome. A case report.
Enhanced cytotoxicity through concomittant application of GM-CSF and chemotherapy.
Long term therapy with G-CSF low-dose in Felty´s Syndrome.
Successful therapy and prevention of infections in Felty syndrome with long-term low dose G-CSF.
Deltastorage pool deficiency associated wiht thrombopenia and giant platelets.
A combination of vitamin D and A analogues induces growth inhibition of AML cell lines.
Deltastorage pool deficiency associated with thrombopenia and giant platelets.
Neopterin as an immunological activation marker in myelodysplastic syndromes.
J. D. Bignon, M. Leforestier, M. Hourmant, G. Klausmann and J. P. Soulillou.
A. Murat, G. Klausmann, H. du Rostu, M. Krempf, B. Charbonnel and J. Guillon.
treated type I diabetic subjects: a rediscovered liberty.
H. v. Lilienfeld-Toal, B. Kampmann, S. Issa, G. Klausmann und H. Frank.
Auswirkungen einer Phosphatbelastung auf den Ca-Stoffwechsel bei beginnender Niereninsuffizienz.
Osteologia 2, P. Dietsch et al. Eds. 1987, W. d. Gruyter.
G. Klausmann, H. v. Lilienfeld-Toal und B. Kampmann.
G. Klausmann, H. v. Lilienfeld-Toal, B. Kampmann, U. Krause und J. Beyer.
G. Kahaly, U. Krause, T. Strack, G. Klausmann, J. Schrezenmeir und J. Beyer.
J. Beyer, G. Schulz, J. Schrezenmeir. T. Strack, H. Achterberg, G. Klausmann und F. Hohlweg.
J. Schrezenmeir und G. Klausmann.
G: Klausmann, H. v. Lilienfeld-Toal, P. Schäfer, U. Krause, B. Kampmann und J. Beyer.
H. Lehnert, G Klausmann et al.
G. Klausmann, H. v. Lilienfeld-Toal, P. Schäfer, U. Krause, J. Schrezenmeir und J. Beyer.
G. Klausmann, C. Erbil, D. Bittinger, G. Adler und P. v.
Growth Factor II Produktion eines fibrösen Mesothelioms.
G. Klausmann, G. Adler, C. Erbil, D. Bittinger, T. Braulke, W. Blum, P. v. Wichert.
Severe tumor hypoglycemia associated with increased production of Insulin-Like Growth factor II by a fibrous mesothelioma.
Factor II mRNA expression by a fibrous mesothelioma.
4th Int. Cong. on Hormones and Cancer, 1991.
Modell einer sinnvollen computerunterstützten Diabetikerbetreuung an einer Klinik ohne Diabetesstation.
Akt. Endokr. Stoffw. 12 (1991): 266-267.
Funktionsprüfung der Gallenblase und Cholecystolithiasis bei Zustand nach totaler Gastrektomie.
Hat die Elastase einen Einfluss auf die diabetische Retinopathie?
Therapiefolgestörungen und Gewichtsverlauf nach unterschiedlichen Gastrektomieverfahren in der Frührehabilitation.
Maintenance of decreased cardiovascular risk factors and improved metabolic control by an intensified teaching program in obese NIDDM patients.
Lowering the cost of treatment by improved metabolic control with an intensified treatment and teaching program in obese NIDDM patients.
Improved metabolic control and maintenance of lifestyle changes with an intensified teaching program in obese NIDDM patients.
Reduction of Plasma Plasminogen Acvtivator Inhibitor Type I (PAI-I) concentration during weight loss in obese patients.
Deutliche Reduktion des kardiovaskulären Risikos übergewichtiger Typ II Diabetiker durch ein intensives Schulungsprogramm.
Dauerhaft gebesserte Stoffwechselparameter und veränderte Essgewohnheiten durch ein intensives Schulungsprogramm für Übergewichtige Typ II Diabetiker.
Reduction of increased plasma Plasminogen Activator Inhibitor Typ I (PAI-I) levels during weight loss in obese patients.
Reduzierung erhöhter Plasminogen-Aktivator-Inhibitor Typ I (PAI-I) Plasmaspiegel während signifikanter Gewichtsabnahme bei adipösen Patienten.
Dauerhaft gebesserte Stoffwechselparameter und veränderte Eßgewohnheiten durch ein intnsiviertes Schulungsprogramm für Übergewichtige.
Reduction of increased Plasma Plasminogen Actvator Inhibitor Typ I (PAI-I) levels during weight loss in obese NIDDM patients.
Volumen und Kontraktilität der Gallenblase nach Cisaprid-Gabe bei adipösen Patienten unter Gewichtsreduktion.
Decrease of elevated PAI-I plasma levels during weight reduction in obese diabetic and non-diabetic individuals.
Improvement of diabetes care and lowering the cost of treatment with an intensified teaching program in obese NIDDM patients.
Improved fibrinolysis by reduced plasma plasminogen activator inhibitor (PAI-I) levels during weight loss in obese NIDDM patients.
Advantage of a 1500 Kcal carbohydrate rich diet versus a normal 800 Kcal restriction diet in obese patients.
Significant decrease of elevated plasma plasminogen activator inhibitor typ-I (PAI-I) levels during weight loss in obese NIDDM patients.
Elevated PAI-I plasma levels decrease during weight reduction in obese diabetic and non-diabetic individuals.
Decrease of elevated plasma plasminogen activator type I (PAI-I) activity during weight loss in obese patients.
Ist eine Anschlußheilbehandlung bei Patienten mit Typ II Diabetes sinnvoll?
Signifikant gebesserte Diabeteseinstellung nach Anschlußheilbehandlung bei Typ I Diabetikern.
Improved fibrinolysis by reduced plasma plasminogen activator inhibitor typ I (PAI-I) activity during weight loss in obese NIDDM patients.
Deutlicher Vorteil einer 1500 Kcal kohlenhydratreicher Kost (KHR) gegenüber einer 800 Kcal Reduktionskost (RK) bei übergwichtigen Patienten.
Opposite variations fibrinogen plasma levels in overweight typ 2 diabetics and Nondiabetics during weight loss.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v.

 v.